Georgia Capital PLC
LSE:CGEO

Watchlist Manager
Georgia Capital PLC Logo
Georgia Capital PLC
LSE:CGEO
Watchlist
Price: 4 065 GBX -1.57% Market Closed
Market Cap: £1.4B

Georgia Capital PLC
Investor Relations

Georgia Capital Plc is a holding company, which engages in the investment and development of businesses in Georgia with holdings in industries. The Company’s primary business is to develop or buy businesses, help them institutionalize their management and grow them into mature businesses. The Georgia Capital has six private businesses: a healthcare services business; a water utility business; a retail (pharmacy) business and insurance business (P&C and medical insurance); a renewable energy business, and an education business. The five businesses in its other private portfolio are Housing Development, Hospitality and Commercial Real Estate, Beverages, Auto Services and Digital Services. Georgia Capital normally seeks to monetize its investment over a 5-10 year period from an initial investment. The Company’s beverage business combines three business lines, including wine business, beer business and distribution business.

Show more
Loading
CGEO
FTSE All Share Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 27, 2025
AI Summary
Q3 2025

NAV Growth: Net asset value (NAV) per share grew nearly 8% in Q3, driven by strong operating performance and share price gains in key holdings.

Outstanding Portfolio Results: Large private portfolio companies delivered nearly 30% EBITDA growth in Q3, continuing a trend of 30%+ growth over nine months.

Buybacks & Capital Return: Over 1.4 million shares bought back in Q3; progress on the GEL 700 million capital return program is ahead of schedule, with nearly half already executed.

Deleveraging: Holding company net debt reduced significantly, now targeting a debt-free position; NCC ratio improved to 5.4%, nearly three times lower year-on-year.

Segment Performance: Retail pharmacy, insurance, and healthcare businesses all reported double-digit revenue and EBITDA growth, with record high profitability and strong cash flows.

Dividend Outlook Raised: Expected portfolio company dividend inflows for the year increased to around GEL 200 million, with per share inflows up 31% due to reduced share count.

Positive Economic & Market Backdrop: Management highlighted robust macroeconomic conditions and local capital market activity, supporting continued business growth and value creation.

Buyback Remains Priority: Management confirmed that buybacks are preferred over further debt reduction at current NAV discount levels.

Key Financials
NAV per Share
7.9% increase in Q3
EBITDA Growth (Large Portfolio Companies)
29.5% in Q3; 34% over 9 months
Revenue Growth
13.5% in Q3; 16.2% over 9 months
Free Cash Flow
$63 million (pro forma, post debt paydown)
Free Cash Flow per Share
45.6% increase
NCC Ratio
5.4%
Shares Bought Back
1.4 million in Q3; 15.2 million total
Retail Pharmacy EBITDA
GEL 73.7 million (9 months)
Retail Pharmacy Gross Profit Margin
33.4% in Q3
Adjusted Net Debt to LTM EBITDA (Pharmacy)
1.3x
Retail Pharmacy Dividends
GEL 35 million (expected for year)
Insurance Revenue Growth
9% in Q3; nearly 30% over 9 months
Insurance Pre-tax Profit Growth
22% in Q3; 23% over 9 months
Insurance ROE (P&C)
>40%
Insurance Combined Ratio (P&C)
83%
Insurance Renewal Rate (P&C)
75%
Insurance Net Premiums Written (P&C)
14% growth
Insurance Market Share (P&C)
35%
Insurance Net Premiums Written (Medical)
8% growth
Insurance ROE (Medical)
About 38%
Insurance Renewal Rate (Medical)
80%
Healthcare Outpatient Revenue Growth
28% in Q3
Healthcare EBITDA Growth
46% in Q3
Healthcare EBITDA Margin
>19% in Q3
Healthcare LTM EBITDA
GEL 89 million
Healthcare Net Debt to EBITDA
3.8x
Healthcare Hospital Revenue Growth
19% in Q3 2025
Healthcare Hospital EBITDA Growth
44% in Q3 2025
Healthcare Operating Cash Flow Growth
39% (9 months 2025)
Hospital Occupancy Rate
Up 8.5 percentage points in Q3
Hospital Average Length of Stay
Decreased by 0.3 days
Polyclinics Admissions Growth
8%
Diagnostics Tests Performed Growth
15%
Diagnostics Revenue Growth
26%
Diagnostics EBITDA Growth
55%
Portfolio Company Dividend Inflows
GEL 200 million (expected for year)
Dividend Inflows Per Share Growth
31%
Liquidity
$77 million at quarter-end
Earnings Call Recording
Other Earnings Calls

Management

Mr. Irakli Gilauri
Chairman & CEO
No Bio Available
Mr. Giorgi Alpaidze
Chief Financial Officer & Deputy CEO
No Bio Available
Mr. Giorgi Ketiladze
MD & Head of Investments
No Bio Available
Mr. Levan Dadiani
General Counsel
No Bio Available
Mr. Avtandil Namicheishvili
Deputy Chief Executive Officer
No Bio Available
Ms. Eka Duchidze
Executive Director
No Bio Available
Ms. Ia Gabunia
Chief Strategy Officer
No Bio Available
Mr. Gigi Getia C.F.A.
Senior Director of Investments
No Bio Available
Ms. Nino Vakhvakhishvili
Chief Economist
No Bio Available
Mr. Irakli Gogia
Portfolio Manager, CEO at Retail (Pharmacy), Hospitals, Medical Insurance and Clinics & Diagnostics
No Bio Available

Contacts

Address
London
84 Brook Street
Contacts
+442031784052.0
georgiacapital.ge
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett